China, the first country worldwide to approve a gene therapy in 2003, almost lost the advantage for a head start in cell and gene therapy (CGT) development due to a lack of clear and strict regulatory frameworks. The rapid advancements of CGTs' development worldwide as well as their therapeutic potential have triggered the government to conduct a spate of regulatory reforms to promote normative development of CGTs in China. Encouraged by policy support, the remarkable progress for CGTs in China has been observed over the past few years, thereby catapulting China back into the forefront of CGTs worldwide. This article aims to provide an overview of regulatory reforms, the current development landscape of CGTs, as well as key contributors and challenges for CGT development in China.
Get full access to this article
View all access options for this article.
References
1.
SalzmanR, CookF, HuntT, et al.Addressing the value of gene therapy and enhancing patient access to transformative treatments. Mol Ther, 2018; 26:2717–2726.
2.
WangD, WangK, CaiY. An overview of development in gene therapeutics in China. Gene Ther, 2020; 27:338–348.
3.
ChengB, LuS-l, FuX-b. Regenerative medicine in China: main progress in different fields. Military Med Res, 2016; 3:24.
4.
Li AH-f. Whom to Trust When Sick? The Wei Zexi Incident, the Chinese Internet, and the Healthcare System in China. China Perspect, 2016; 2016:79–83.
5.
The National Health and Family Planning Commission of the People's Republic of China held a video and telephone conference on standardizing the management of medical institutions' departments and medical technology management. National Health and Family Planning Commission of the People's Republic of China. www.gov.cn/xinwen/2016-05/05/content_5070534.htm (last accessed December28, 2020).
6.
MasterZ, MatthewsKRW, Abou-el-EneinM. Unproven stem cell interventions: a global public health problem requiring global deliberation. Stem Cell Rep, 2021; 16:1435–1445.
7.
BauerG, ElsallabM, Abou-El-EneinM. Concise review: a comprehensive analysis of reported adverse events in patients receiving unproven stem cell-based interventions. Stem Cells Transl Med, 2018; 7:676–685.
8.
WuW, WangY, TangZ, et al.Regulatory oversight of cell therapy in China: government's efforts in patient access and therapeutic innovation. Pharmacol Res, 2020; 158:104889.
9.
Chinese Academy of Sciences & Technology. Global Science & Technology Trends Report: Gene and Cell Therapy Research & Development. https://www.cas.org/resources/whitepapers/gene-cell-therapy (last accessed January10, 2021).
10.
Center for drug evaluation. www.cde.org.cn/index.jsp (last accessed June20, 2021).
11.
Key points for quality control of human somatic and gene therapy clinical research. Ministry of Health of the People's Republic of China. www.elinklaw.com/zsglmobile/lawView.aspx?id=86561 (last accessed December28, 2020).
12.
New measures for the examination and approval of biological products (council order 1999 no. 3). State Food and Drug Administration. https://www.nmpa.gov.cn/directory/web/nmpa/xxgk/fgwj/bmgzh/19990422094901576.html (last accessed December28, 2020).
13.
Technology guidelines for the quality control of human cell therapy research and preparations. State Food and Drug Administration. https://wenku.baidu.com/view/fed10980abea998fcc22bcd126fff705cc175cfe.html (last accessed December28, 2020).
14.
Technical guidelines for human gene therapy research and formulation quality control. State Food and Drug Administration. http://law.pharmnet.com.cn/laws/detail_845.html (last accessed June20, 2021).
15.
Ethical guiding principles for the research of human embryonic stem cell. Ministry of Health of the People's Republic of China and the Ministry of Science. www.scrcnet.org/download/eccr_31.pdf (last accessed June20, 2021).
16.
Ethical principles for human assisted reproduction technology and human sperm bank. Ministry of Health of the People's Republic of China. www.nhc.gov.cn/qjjys/s3581/200805/f69a925d55b44be2a9b4ada7fcdec835.shtml (last accessed June20, 2021).
17.
The first to allow the clinical application of the Third Category of Medical Technology Directory. Ministry of Health of the People's Republic of China. www.gov.cn/gzdt/2009-06/11/content_1337464.htm (last accessed December28, 2020).
18.
Notice on carrying out clinical research and application of self-examination and self-correction of stem cells. Ministry of Health of the People's Republic of China. www.nhc.gov.cn/zwgkzt/pkjjy1/201201/53890.shtml (last accessed December28, 2020).
19.
Notice of the National Health Commission on the Cancellation of the relevant work on the approval of access to medical applications for the Third Category of Medical Technology. National Health and Family Planning Commission of the People's Republic of China. http://www.nhc.gov.cn/yzygj/s3585/201507/c529dd6bb8084e09883ae417256b3c49.shtml (last accessed December28, 2020).
20.
Notice about application as a Stem Cell Clinical Research Institution. National Health and Family Planning Commission of the People's Republic of China and China Food and Drug Administration. www.nhc.gov.cn/qjjys/s3581/201512/a8ef28444b8e4d4382f06353bb09909c.shtml (last accessed December28, 2020).
21.
Measures for the ethical review of biomedical research involving human subjects. National Health and Family Planning Commission of the People's Republic of China. http://www.nhc.gov.cn/fzs/s3576/201610/84b33b81d8e747eaaf048f68b174f829.shtml (last accessed June20, 2021).
22.
Technical guidelines for research and evaluation of cell therapy products (trial). China Food and Drug Administration. http://www.scrcnet.org/download/eccr_33.pdf (last accessed December28, 2020).
23.
CyranoskiD. WhatCRISPR-baby prison sentences mean for research. https://www.nature.com/articles/d41586-020-00001-y (last accessed June20, 2021).
Civil Code of the People's Republic of China. National Health Commission. http://www.npc.gov.cn/npc/c30834/202006/75ba6483b8344591abd07917e1d25cc8.shtml (last accessed June20, 2021).
26.
Key considerations for cell therapy product application for clinical trial pharmaceutical research and application materials. China Food and Drug Administration. www.cde.org.cn/news.do?method=largeInfo&id=ffacd65c6758298d (last accessed December28, 2020).
27.
Somatic Cell Therapy Clinical Research and Transformation Application Management Measures (Trial) (Draft for comments). National Health Commission. www.nhc.gov.cn/wjw/yjzj/201903/01134dee9c5a4661a0b5351bd8a04822.shtml (last accessed December28, 2020).
28.
Technical guidelines for clinical trials of immune cell therapy products (draft for comments). National Medical Products Administration. www.cde.org.cn/zdyz.do?method=largePage&id=579b0e71dbe89489 (last accessed December28, 2020).
29.
Technical Guidelines for clinical trials of human-derived stem cells and their derived cell therapy products (draft for comments). National Medical Products Administration. www.cde.org.cn/zdyz.do?method=largePage&id=c641b96eaadd68d5 (last accessed December28, 2020).
30.
Technical guidelines for pharmaceutical research and evaluation of gene therapy products (draft for comments). National Medical Products Administration. www.cde.org.cn/news.do?method=largeInfo&id=b167edc6058fc23e (last accessed December28, 2020).
31.
Technical guidelines for pharmaceutical research and evaluation of immune cell therapy products (draft for comments). National Medical Products Administration. www.cde.org.cn/zdyz.do?method=largePage&id=607291fb0b3ee019 (last accessed December28, 2020).
32.
Technical guidelines for pharmaceutical research and evaluation of gene transduction and modification systems (draft for comments). National Medical Products Administration. www.cde.org.cn/zdyz.do?method=largePage&id=2e2336e1fc34169c (last accessed December28, 2020).
33.
Drug Administration Law. National Medical Products Administration. https://www.nmpa.gov.cn/directory/web/nmpa/hudong/zxft/20190918161201286.html (last accessed June20, 2021).
34.
ChaiP, FangC, CynthiaL, et al.Analysis of gene and cell therapy research & development trend. China Biotechnol, 2019; 39:43–52.
35.
Deloitte. Winning in the cell and gene therapies market in China. https://www2.deloitte.com/content/dam/Deloitte/cn/Documents/strategy/deloitte-cn-strategy-and-operation-china-cgt-white-paper-en-200520.pdf (last accessed December2020).
36.
Gene Therapy Trials Worldwide. The Journal of Gene Medicine. https://a873679.fmphost.com/fmi/webd/GTCT (last accessed June2021).
37.
WangJ, GaoY, WangY, et al.Clinical development of CAR T cell therapy in China: 2020 update. Cell Mol Immunol, 2020; 18:792–804.
13th Five-Year Biological Industry Development Plan. National Development and Reform Commission. https://www.ndrc.gov.cn/xxgk/zcfb/ghwb/201701/t20170112_962220.html (last accessed December28, 2020).
40.
Catalogue for Guiding Industry Restructuring (2019 version). National Development and Reform Commission. www.gov.cn/xinwen/2019-11/06/content_5449193.htm (last accessed January10, 2021).
41.
Nuwacell. The national and local authorities' cell industry encouragement policies in 2019. www.nuwacell.com/index.php?c=content&a=show&id=507 (last accessed January10, 2021).
42.
Forward the Economist. A panoramic map of the stem cell medical industry in 2021. https://www.qianzhan.com/analyst/detail/220/201207-8cfce57d.html (last accessed December28, 2020).
43.
BGI. China National Genebank Officially Opens. https://www.bgi.com/%E5%85%B3%E4%BA%8E%E6%88%91%E4%BB%AC/careers/china-national-genebank-officially-opens (last accessed January10, 2021).
44.
BIOTECH. China's first gene and cell therapy hospital will be located in Shenzhen. www.biotech.org.cn/information/155581 (last accessed January10, 2021).
45.
Invest. The Life Garden Cell and Gene Therapy Innovation Center is launched to accelerate the transformation of scientific research. http://invest.beijing.gov.cn/tzbj/tzxm/ssmtjxyxw/202008/t20200803_1969610.html (last accessed January10, 2021).
46.
Jinan Science & Technology Bureau. The country's first cell therapy sharing industry support platform is settled in Jinan. Jinan Science & Technology Bureau. http://jnsti.jinan.gov.cn/art/2020/9/29/art_11657_4680138.html (last accessed January10, 2021).
47.
Vcbeat. The full spectrum of domestic cellular immunotherapy companies in China. https://vcbeat.top/47190 (last accessed December28, 2020).
48.
eMedClub. In 2020,
China's cell and gene therapy financing transactions exceed 15.5 billion yuan CAR-T is still hot. https://wemp.app/posts/49dbf81d-59c2-483a-bb22-4668c0e260c1 (last accessed December28, 2020).
LiJR, WalkerS, NieJB, et al.Experiments that led to the first gene-edited babies: the ethical failings and the urgent need for better governance. J Zhejiang Univ Sci B, 2019; 20:32–38.
51.
Abou-El-EneinM, ElsanhouryA, ReinkeP. Overcoming challenges facing advanced therapies in the EU Market. Cell Stem Cell, 2016; 19:293–297.
52.
GaoJ. The development status of cell therapy industry and supervision in China. Chin Med Biotechnol, 2019; 14:193–198.
53.
Sartotius. How CDMOs can digitalize their cell and gene therapy processes. https://www.sartorius.com/en/knowledge/science-snippets/how-cdmos-can-digitalize-their-cell-and-gene-therapy-processes-751642 (last accessed June20, 2021).
54.
FritscheE, VolkHD, ReinkeP, et al.Toward an optimized process for clinical manufacturing of CAR-Treg cell therapy. Trends Biotechnol, 2020; 38:1099–1112.
55.
WangL, Tan Su YinE, ZhaoH, et al.CAR-T cells: the Chinese experience. Expert Opin Biol Ther, 2020; 20:1293–1308.
56.
SieglerEL, KenderianSS. Neurotoxicity and cytokine release syndrome after chimeric antigen receptor T cell therapy: insights into mechanisms and novel therapies. Front Immunol, 2020; 11:1973.
57.
ExleyAR, RantellK, McBlaneJ. Clinical development of cell therapies for cancer: the regulators' perspective. Eur J Cancer, 2020; 138:41–53.
58.
KNOEMA. China—gross domestic product per capita in current prices. https://knoema.com/atlas/China/GDP-per-capita (last accessed June20, 2021).
59.
JørgensenJ, HannaE, KefalasP. Outcomes-based reimbursement for gene therapies in practice: the experience of recently launched CAR-T cell therapies in major European countries. J Mark Access Health Policy, 2020; 8:1715536.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
